Quartz8d agobearish
Merck cuts 2026 profit forecast on Terns acquisition chargesThe pharma giant now expects adjusted earnings of $2.66 to $2.76 per share, down from a prior range of $5.04 to $5.16
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
326last 24h
2138last 7d
379● bullish (7d)
188● bearish (7d)
204publishers
The Wall Street Journal8d agobearish
Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom LineMerck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.